← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
CTT PHARMACEUTICAL HOLDINGS, INC.
Chief Executive Officer | Director
Identity: SEC owner CIK matched through an unambiguous cached owner-name crosswalk · Reporting-owner CIK: 0001035422
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 18
- Purchases · 24M
- 32
- Average purchase
- $1.0K
- Median purchase
- $522
- Gross purchase value
- $32.1K
Companies: CTT PHARMACEUTICAL HOLDINGS, INC.
32 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-10-06 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $204 | Open filing |
| 2026-09-29 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $505 | Open filing |
| 2026-09-28 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $204 | Open filing |
| 2026-09-22 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $505 | Open filing |
| 2026-09-16 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $545 | Open filing |
| 2026-09-10 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $175 | Open filing |
| 2026-09-04 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $490 | Open filing |
| 2026-09-02 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $150 | Open filing |
| 2026-08-31 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $175 | Open filing |
| 2026-08-24 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $126 | Open filing |
| 2026-08-20 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $575 | Open filing |
| 2026-08-19 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $600 | Open filing |
| 2026-08-14 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $108 | Open filing |
| 2026-08-10 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $539 | Open filing |
| 2025-12-17 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $498 | Open filing |
| 2025-11-24 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Director | $8.0K | Open filing |
| 2025-11-21 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $2.5K | Open filing |
| 2025-10-31 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $420 | Open filing |
| 2025-10-07 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $409 | Open filing |
| 2025-09-23 | CTT PHARMACEUTICAL HOLDINGS, INC. | CTTH | Chief Executive Officer | $2.2K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 0/31
- Large purchase ≥ $100k
- 0/32
- Cluster buying · 15D
- 0/32
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.